Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-PSMA-617 + Cabazitaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-PSMA-617 | AAA817|[225Ac]Ac-PSMA-617|Actinium Ac 225 vipivotide tetraxetan | 225Ac-PSMA-617 is a 225Ac-labeled PSMA-targeting ligand that may inhibit growth of PSMA-expressing tumors (PMID: 27390158). | ||
| Cabazitaxel | Jevtana | XRP6258|RPR-116258A | Antimicrotubule Agent 14 | Jevtana (cabazitaxel) inhibits microtubule depolymerization by binding to tubulin, resulting in cell cycle arrest and decreased tumor cell proliferation (PMID: 32660451). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|